Home » Stocks » MRVI

Maravai LifeSciences Holdings, Inc. (MRVI)

Stock Price: $36.47 USD 3.95 (12.15%)
Updated Mar 1, 2021 4:00 PM EST - Market closed
After-hours: $36.58 +0.11 (0.30%) Mar 1, 7:29 PM
Market Cap 9.27B
Revenue (ttm) 221.71M
Net Income (ttm) 58.37M
Shares Out 267.84M
EPS (ttm) 0.22
PE Ratio 167.35
Forward PE 56.82
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $36.47
Previous Close $32.52
Change ($) 3.95
Change (%) 12.15%
Day's Open 34.77
Day's Range 33.49 - 36.87
Day's Volume 1,226,974
52-Week Range 23.62 - 37.79

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 23 hours ago

SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is sched...

GlobeNewsWire - 2 weeks ago

Advancement Expected to Further Accelerate Development of mRNA Vaccines and Therapeutics Advancement Expected to Further Accelerate Development of mRNA Vaccines and Therapeutics

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences , Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators...

Investors Business Daily - 1 month ago

Stocks Rebound; Qualcomm, Maravai, One Medical Clear Buy Points

Stocks rebound, Qualcomm, Maravai, One Medical clear buy points. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, st...

Other stocks mentioned: ONEM, QCOM
GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators,...

Seeking Alpha - 3 months ago

Maravai LifeSciences has received a welcome public debut. The company provides a crucial role in drug development and in fact even in the Pfizer/BioNTech vaccine.

GlobeNewsWire - 3 months ago

SAN DIEGO, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and bi...

Benzinga - 3 months ago

Maravai Life Sciences Holdings (NASDAQ:MRVI) will hit the public markets with perfect timing as it sees its mRNA product used by COVID-19 vaccine makers. The Offering: Maravai Life Sciences pl...

About MRVI

Maravai LifeSciences Holdings operates as a life sciences company that provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in thr... [Read more...]

Industry
Biotechnology
IPO Date
Nov 20, 2020
CEO
Carl W. Hull
Employees
390
Stock Exchange
NASDAQ
Ticker Symbol
MRVI
Full Company Profile

Financial Performance

In 2019, MRVI's revenue was $143.14 million, an increase of 15.59% compared to the previous year's $123.83 million. Losses were -$4.47 million, -0.04% less than in 2018.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for MRVI stock is "Strong Buy." The 12-month stock price forecast is 33.67, which is a decrease of -7.68% from the latest price.

Price Target
$33.67
(-7.68% downside)
Analyst Consensus: Strong Buy